Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

New HIV Prevention Drug Approved—Now Let’s Remove the Final Barrier

by June 19, 2025
June 19, 2025
New HIV Prevention Drug Approved—Now Let’s Remove the Final Barrier

Jeffrey A. Singer

The Food and Drug Administration approved a new injectable drug on June 18 that provides pre-exposure prophylaxis (PrEP) against HIV, requiring individuals to take it only twice a year. By removing barriers to access for adults and adolescents, the FDA makes the drug, lenacapavir (brand name Yetzugo), more widely available—great news for HIV prevention. Manufactured by Gilead Sciences, clinical trials have shown that the drug offers over 99.9 percent protection against HIV for six months.

In late 2021, the FDA removed barriers to another injectable PrEP, cabotegravir (Apretude). This medication provides protection that lasts for two months, necessitating bimonthly injections.

Like all other forms of PrEP and PEP (post-exposure prophylaxis), the government requires individuals to obtain a prescription from a state-licensed health care provider to access these injectables.

Both injectables are quite costly. Yetzugo’s list price is $28,218. The FDA already permits patients with treatment-resistant HIV to access the drug, using a different administration protocol, under the brand name Sunlenca, at a cost of over $42,000 per year. The list price of Apretude is $4,025 every two months.

By contrast, a month’s supply of the daily pills Truvada and Descovy runs about $2,000 for those without insurance. And the generic version of Truvada (emtricitabine/​tenofovir) sells for a dollar per pill.

Gilead points out that most people won’t have to pay the full price for Yetzugo. Third-party payers will cover the costs. Commercial insurance carriers will likely incorporate the expense into the premiums they charge beneficiaries, and government-funded health plans, such as Medicaid, may include it in their budgets. Gilead also plans to offer patient assistance programs to qualified individuals.

As I have written before, the FDA should reclassify all forms of PrEP and PEP as over-the-counter (OTC) drugs. Doing so would not only eliminate the time and money spent on a visit to a clinician’s office for a prescription, but experience shows that drug prices tend to drop when they transition from prescription-only status to over-the-counter availability. Reclassifying these drugs as OTC helps to remove the stigma that some individuals face when seeking PrEP and PEP, while also enhancing privacy. Like emergency contraceptives, OTC PrEP and PEP could even be sold in vending machines.

At least 10 states have enacted workarounds to the FDA’s prescription requirement for PrEP and PEP by expanding the scope of practice of pharmacists (state-licensed health care providers) to prescribe these drugs to individuals. These state-level reforms highlight a growing recognition that federal prescription requirements are outdated and counterproductive.

As I write in my book, Your Body, Your Health Care:

Removing unnecessary prescription requirements would unburden consumers of the unnecessary time and financial costs of visiting a doctor to obtain a prescription and waiting for a pharmacist to fill it. Consumers would also have many convenient options for purchasing OTC medications, including online services, convenience stores, airport newsstands, grocery stores, vending machines, and more. Low-income people who struggle to pay medical bills and who might otherwise forgo necessary treatment will clearly benefit from a reduction in costs.

Reclassifying PrEP and PEP as over-the-counter drugs would be a straightforward, evidence-based step toward broader access and improved public health. Life-saving medications shouldn’t be locked behind unnecessary regulatory barriers—especially when convenience, cost, and stigma continue to be significant obstacles. With powerful new options like Yetzugo now available, it’s time to empower individuals to take charge of their own HIV prevention. We shouldn’t need permission to protect ourselves. The FDA should get out of the way.

0
FacebookTwitterGoogle +Pinterest
previous post
Business mobility: how a car becomes your business tool (and why it’s important to pay attention to the details)
next post
Flaring Iran nuclear crisis provides first major test for pivotal Trump trio

You may also like

As GLP-1 Drug Shortage Ends, Why Will Patients...

October 11, 2024

India Poised to Scrap its Jones Act

September 22, 2023

Opposing War with Iran Shouldn’t Keep You Out...

November 15, 2024

Does Capturing Drug Kingpins Reduce Violence?

August 8, 2024

David Boaz: Champion of Educational Freedom

June 7, 2024

Fifth Circuit Rejects Immunity for Pasadena Police Who...

July 21, 2023

Friday Feature: Masterpiece Academy

June 28, 2024

81 Percent Say They Can’t Afford to Pay...

April 14, 2025

Catastrophic Enrollment Declines at Some Community Colleges

May 1, 2023

Dear Health Reporters: Prep for Biden’s Proposed Rule...

June 29, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • GreenGeeks vs InMotion: Comparing Speed, Uptime, and Support

      July 10, 2025
    • Trump taps Sean Duffy to serve as interim NASA chief

      July 10, 2025
    • Rapidrop secures multi-million pound investment from BGF to fire up international expansion

      July 10, 2025
    • Watchdog backs Rubio’s sanctions on UN official over ‘shameful efforts’ targeting US, Israel

      July 10, 2025
    • Seizing AI’s Trillion Dollar Cyber Opportunity

      July 9, 2025
    • Biden doctor pleads the Fifth in speedy House closed-door interview

      July 9, 2025

    Categories

    • Business (8,431)
    • Investing (2,112)
    • Politics (15,988)
    • Stocks (3,197)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved